ARISTADA and ARISTADA INITIO Drug Insight
“ARISTADA and ARISTADA INITIO Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about ARISTADA and ARISTADA INITIO for schizophrenia in the US market. A detailed picture of the ARISTADA and ARISTADA INITIO for schizophrenia in the United States for the study period 2019 –2032 is provided in this report along with a detailed description of the ARISTADA and ARISTADA INITIO for schizophrenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ARISTADA and ARISTADA INITIO market forecast analysis for schizophrenia in the US, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in schizophrenia.
Drug Summary
ARISTADA (aripiprazole lauroxil) is an atypical antipsychotic available as a white to off-white sterile aqueous extended-release suspension for intramuscular injection. It is available in the following strengths and deliverable volumes from single-use, prefilled syringes: 441 mg (1.6 mL), 662 mg (2.4 mL), and 882 mg (3.2 mL). In addition, its inactive ingredients are sorbitan monolaurate, polysorbate 20, sodium chloride, sodium phosphate dibasic anhydrous, sodium phosphate monobasic, and water for injection.
ARISTADA is also available in the market as ARISTADA INITIO. The ARISTADA INITIO regimen delivers relevant levels of aripiprazole to patients within 4 days of beginning treatment, which may present an alternative to the 21-day initiation period required before beginning long-term ARISTADA therapy and gives health care professionals another tool to help patients during treatment.
The combination of ARISTADA INITIO and a single 30 mg dose of oral aripiprazole can be used to initiate any dose of ARISTADA, the first dose of which can be given on the same day or up to ten subsequent days.
While both ARISTADA and ARISTADA INITIO are made of aripiprazole lauroxil, they have different pharmacokinetic profiles. ARISTADA INITIO uses Alkermes’ NanoCrystal technology and is intended to deliver an extended-release formulation while using a smaller particle size of aripiprazole lauroxil than ARISTADA; to allow faster dissolution and rapid achievement of relevant aripiprazole levels.
Dosage and administration
SECUADO transdermal system is a translucent rounded square product available in three dosages. ARISTADA is only to be administered as an intramuscular injection by a healthcare professional. Depending on the individual patient’s needs, treatment with ARISTADA can be initiated at a dose of 441, 662, or 882 mg administered monthly, corresponding to 300, 450, and 600 mg of aripiprazole, respectively. Treatment may also be initiated with the 882 mg dose every 6 weeks. Administer ARISTADA either in the deltoid muscle (441 mg dose only) or gluteal muscle (441, 662, or 882 mg).
Mechanism of action
ARISTADA is a prodrug of aripiprazole. Following intramuscular injection, the drug is converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. The mechanism of action of aripiprazole in the body is unknown. However, efficacy could be mediated through a combination of partial agonist activity at D2 and 5¬HT1A receptors and antagonist activity at 5-HT2A receptors. Actions at receptors other than D2, 5¬HT1A, and 5-HT2A could explain some of the adverse reactions of aripiprazole (e.g., the orthostatic hypotension observed with aripiprazole may be explained by its antagonist activity at adrenergic alpha1 receptors)
Scope of the Report
The report provides insights into:
A comprehensive product overview including the ARISTADA and ARISTADA INITIO description, mechanism of action, dosage and administration, research and development activities in schizophrenia.
Elaborated details on ARISTADA and ARISTADA INITIO regulatory milestones and other development activities have been provided in this report.
The report also highlights the ARISTADA and ARISTADA INITIO research and development activities in schizophrenia across the United States.
The report also covers the patents information with expiry timeline around ARISTADA and ARISTADA INITIO.
The report contains forecasted sales of for schizophrenia till 2032.
Comprehensive coverage of the late-stage emerging therapies for schizophrenia.
The report also features the SWOT analysis with analyst views for ARISTADA and ARISTADA INITIO in schizophrenia.
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ARISTADA and ARISTADA INITIO Analytical Perspective by DelveInsight
In-depth ARISTADA and ARISTADA INITIO Market Assessment
This report provides a detailed market assessment of ARISTADA and ARISTADA INITIO for schizophrenia in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
ARISTADA and ARISTADA INITIO Clinical Assessment
The report provides the clinical trials information of ARISTADA and ARISTADA INITIO for schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
In the coming years, the market scenario for schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARISTADA and ARISTADA INITIO dominance.
Other emerging products for schizophrenia are expected to give tough market competition to ARISTADA and ARISTADA INITIO and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARISTADA and ARISTADA INITIO in schizophrenia.
Our in-depth analysis of the forecasted sales data of ARISTADA and ARISTADA INITIO from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ARISTADA and ARISTADA INITIO in schizophrenia.
Key Questions
What is the product type, route of administration and mechanism of action of ARISTADA and ARISTADA INITIO?
What is the clinical trial status of the study related to ARISTADA and ARISTADA INITIO in schizophrenia and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARISTADA and ARISTADA INITIO development?
What are the key designations that have been granted to ARISTADA and ARISTADA INITIO for schizophrenia?
What is the forecasted market scenario of ARISTADA and ARISTADA INITIO for schizophrenia?
What are the forecasted sales of ARISTADA and ARISTADA INITIO in the United States?
What are the other emerging products available and how are these giving competition to ARISTADA and ARISTADA INITIO for schizophrenia?
Which are the late-stage emerging therapies under development for the treatment of schizophrenia?
